Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

被引：0
作者：
Evan A. Stein
Frederick Raal
机构：
[1] Metabolic and Atherosclerosis Research Center,Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences
[2] University of Witwatersrand,undefined
来源：
Cardiovascular Drugs and Therapy | 2016年 / 30卷
关键词：
Lipoprotein(a); PCSK9 inhibitors; Niacin; Statins; CETP inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly genetically determined. Emerging therapeutic agents which have recently become available, or which are undergoing clinical trials, can significantly lower Lp(a) levels. Studies with these agents will hopefully be able to provide more direct information whether reductions in Lp(a) will reduce CVD events independently of reduction in LDL-cholesterol levels.
引用
收藏
页码：101 / 108
页数：7
相关论文
共 255 条
  • [1] Boerwinkle E(1992)Apolipoprotein (a) gene accounts for greater than 90 % of the variation in plasma lipoprotein (a) concentrations J Clin Invest 90 52-60
  • [2] Leffert C(1994)The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate J Clin Invest 93 2758-63
  • [3] Lin J(2012)Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) study Circulation 125 241-49
  • [4] Lackner C(1991)Relationship of lipoprotein(a) to variables of coagulation and fibrinolysis in a healthy population Clin Chem 37 1950-4
  • [5] Chiesa G(2013)Lipoprotein(a) metabolism: potential sites for therapeutic targets Metabolism 62 479-91
  • [6] Hobbs HH(2013)Estrogens and cardiovascular disease risk revisited: the Women’s Health Initiative Curr Opin Lipidol 24 493-99
  • [7] Rader DJ(1982)The natural history of coronary heart disease: prognostic factors after recovery from myocardial infarction in 2789 men. the 5-year findings of the coronary drug project Circulation 66 401-14
  • [8] Cain W(1993)The relationship between serum levels of lipoprotein (a) and proteins associated with acute phase response Clin Chim Acta 223 73-82
  • [9] Ikewaki K(1989)Transient changes of serum lipoprotein(a) as an acute phase protein Atherosclerosis 78 145-150
  • [10] Virani SS(1993)The immediate effect of streptokinase on serum lipoprotein (a) concentration and the effect of myocardial infarction on serum lipoprotein (a), apolipoprotein A1 and B, lipids and C-reactive protein Atherosclerosis 103 65-71
12345678910